432 related articles for article (PubMed ID: 34649219)
1. Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment.
Liang C; Li J; Tian B; Tian L; Liu Y; Li J; Xin L; Wang J; Fu C; Shi Z; Xia J; Liang Y; Wang K
Biomed Pharmacother; 2021 Dec; 144():112298. PubMed ID: 34649219
[TBL] [Abstract][Full Text] [Related]
2. Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition.
Nguyen G; Park SY; Le CT; Park WS; Choi DH; Cho EH
Biochem Biophys Res Commun; 2018 Jan; 495(4):2649-2656. PubMed ID: 29278707
[TBL] [Abstract][Full Text] [Related]
3. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.
Kimura T; Singh S; Tanaka N; Umemura T
Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271
[TBL] [Abstract][Full Text] [Related]
4. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
5. Succinate causes α-SMA production through GPR91 activation in hepatic stellate cells.
Li YH; Woo SH; Choi DH; Cho EH
Biochem Biophys Res Commun; 2015 Aug; 463(4):853-8. PubMed ID: 26051274
[TBL] [Abstract][Full Text] [Related]
6. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.
Wree A; Mehal WZ; Feldstein AE
Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930
[TBL] [Abstract][Full Text] [Related]
7. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.
Xu JY; Li ZP; Zhang L; Ji G
World J Gastroenterol; 2014 Oct; 20(37):13493-500. PubMed ID: 25309079
[TBL] [Abstract][Full Text] [Related]
8. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
9. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.
Oniciu DC; Hashiguchi T; Shibazaki Y; Bisgaier CL
PLoS One; 2018; 13(5):e0194568. PubMed ID: 29847555
[TBL] [Abstract][Full Text] [Related]
10. HWL-088, a new and highly effective FFA1/PPARδ dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis.
Hu L; Zhou Z; Deng L; Ren Q; Cai Z; Wang B; Li Z; Wang G
J Pharm Pharmacol; 2020 Nov; 72(11):1564-1573. PubMed ID: 32734608
[TBL] [Abstract][Full Text] [Related]
11. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).
Grattagliano I; Di Ciaula A; Baj J; Molina-Molina E; Shanmugam H; Garruti G; Wang DQ; Portincasa P
Methods Mol Biol; 2021; 2310():201-246. PubMed ID: 34096005
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
[TBL] [Abstract][Full Text] [Related]
13. Sirtuin 3 (SIRT3) Regulates α-Smooth Muscle Actin (α-SMA) Production through the Succinate Dehydrogenase-G Protein-coupled Receptor 91 (GPR91) Pathway in Hepatic Stellate Cells.
Li YH; Choi DH; Lee EH; Seo SR; Lee S; Cho EH
J Biol Chem; 2016 May; 291(19):10277-92. PubMed ID: 26912655
[TBL] [Abstract][Full Text] [Related]
14. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis.
Lambrecht J; van Grunsven LA; Tacke F
Expert Opin Pharmacother; 2020 Sep; 21(13):1637-1650. PubMed ID: 32543284
[TBL] [Abstract][Full Text] [Related]
16. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH).
Lee JH; Oh JY; Kim SH; Oh IJ; Lee YH; Lee KW; Lee WH; Kim JH
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33050067
[TBL] [Abstract][Full Text] [Related]
18. Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice.
Du M; Wang X; Yuan L; Liu B; Mao X; Huang D; Yang L; Huang K; Zhang F; Wang Y; Luo X; Wang C; Peng J; Liang M; Huang D; Huang K
J Hepatol; 2020 Dec; 73(6):1333-1346. PubMed ID: 32717288
[TBL] [Abstract][Full Text] [Related]
19. Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances.
Cruz-Ramón V; Chinchilla-López P; Ramírez-Pérez O; Méndez-Sánchez N
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s58-s67. PubMed ID: 29080343
[TBL] [Abstract][Full Text] [Related]
20. Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation.
Liu XJ; Xie L; Du K; Liu C; Zhang NP; Gu CJ; Wang Y; Abdelmalek MF; Dong WY; Liu XP; Niu C; Yang C; Diehl AM; Wu J
Liver Int; 2020 Apr; 40(4):830-843. PubMed ID: 31903720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
